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Abstract 
Background: In addition to achieving good glycemic control, diabetes care management aims to improve the qual-
ity of life (QOL) in patients. Treatment-associated difficulties and side effects frequently cause deterioration in QOL. 
Liraglutide, a GLP-1 receptor agonist, is a novel injection drug that promotes insulin secretion. It is a user-friendly, 
once-daily injection with fewer hypoglycemic events. In this study, we aimed to examine the effect of liraglutide 
therapy on QOL in patients.
Methods: In total, 304 insulin- and liraglutide-naïve patients with type 2 diabetes were enrolled in this observational 
study; they received liraglutide therapy for 12 weeks. The main outcome measure was change in QOL from baseline, 
which was assessed using diabetes therapy-related QOL (DTR-QOL).
Results: At week 12, liraglutide significantly decreased HbA1c levels (8.7 ± 1.5 vs. 7.5 ± 1.3, p < 0.001) and BMI 
(27.9 ± 5.3 vs. 27.3 ± 5.2, p < 0.001). According to the QOL scores, although the treatment modality had changed 
from non-injection to injection therapy, liraglutide improved patient satisfaction with treatment. Significant correla-
tions were found between change in HbA1c level and satisfaction with treatment, as well as between change in body 
weight and burden on social and daily activities, anxiety and dissatisfaction with treatment, and hypoglycemia.
Conclusions: Liraglutide significantly improved glycemic control and reduced the body weight without deteriorat-
ing QOL in obese patients with type 2 diabetes.
Trial registration UMIN-CTR: UMIN000007159
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Background
The prevalence of type 2 diabetes mellitus (T2DM) has 
been increasing worldwide. Japan is one of the coun-
tries with the highest prevalence rates in the world [1], 
which was promoted by the adoption of high-fat west-
ernized diet patterns and sedentary lifestyle due to the 
rise of automation. The persistent elevation of blood 
glucose level causes microvascular and life-threatening 
macrovascular complications resulting in low quality of 
life (QOL) in patients with diabetes.
Recent evidence suggests that good glycemic control 
is necessary to prevent diabetic complications. How-
ever, many patients with T2DM have difficulty achieving 
and maintaining glycemic control. One of the obstacles 
is that patients have to stick to a daily routine for a long 
period to maintain good glycemic control [2]. Another 
possible barrier includes the side effects of medical treat-
ment including hypoglycemia or weight gain or both, 
which may arouse anxiety [3], decrease motivation, 
and lower the QOL [4] in patients. Patients often fail to 
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psychological stressors, which lead to a downward spiral 
of neglected diabetes care [5]. In particular, most patients 
have a negative attitude towards insulin injection [6], and 
consider it a critical-state treatment [7]. They become 
hesitant about the initiation of insulin therapy despite 
the fact that it is a reliable means to control blood glucose 
[8], which may result in late insulin initiation [9]. Thus, it 
is very important to attain good glycemic control without 
reducing patient motivation or QOL.
Liraglutide is a glucagon-like peptide-1 (GLP-1) recep-
tor agonist. As GLP-1 receptor agonists promote insu-
lin secretion in a blood glucose-dependent fashion, they 
cause fewer hypoglycemic episodes in comparison with 
sulfonylureas [10]. In addition, they can achieve long-
term glycemic control with only one shot per day [11]. 
GLP-1 receptor agonists have other beneficial effects, 
such as suppression of appetite, delayed gastric emptying, 
and weight loss. These favorable features of liraglutide are 
expected to solve many of the unmet medical needs asso-
ciated with T2DM treatment. However, it has been sug-
gested that patients and physicians may be reluctant to 
implement liraglutide treatment because GLP-1 receptor 
agonists are injection drugs [4]. Therefore, it is important 
to elucidate the impact of liraglutide therapy on clinical 
parameters and QOL as well as its side effects in patients 
with T2DM.
We aimed to examine the effects of liraglutide on gly-
cemic control, body weight, and QOL score in obese 
Japanese patients with T2DM in patient’s psychologi-




We conducted a prospective, multicenter, pre-post 
observational study to examine the effect of liraglutide 
on QOL in Japanese patients with T2DM from Febru-
ary 2012 to September 2013 at 66 medical institutions 
in Japan listed in the Additional file 1. The inclusion cri-
teria were (1) type 2 diabetes, (2) no prior use of insulin 
or liraglutide, and (3) aged 15  years and older. Patients 
with malignant tumors and pregnant or nursing women 
were excluded from this study. At the start of the study, 
only patients with dietary therapy, physical therapy, or 
sulfonylurea treatment were allowed to enroll because 
only they were allowed to use liraglutide under insurance 
coverage in Japan. During the course of the study, oral 
hypoglycemics other than sulfonylurea were reimbursed. 
Therefore, patients using those drugs were enrolled at 
later time points.
No pre-specified initiation or titration protocol for 
liraglutide was used. The participating physicians were 
allowed to determine the initial dose, maintenance dose, 
and timing of liraglutide administration by consider-
ing the patient’s condition and side effects. Clinical and 
laboratory parameters and diabetes therapy-related 
QOL (DTR-QOL) scores [12] were measured before (at 
baseline) and 12  weeks after the initiation of liraglutide 
therapy. In addition, at baseline and week 12, the hypo-
glycemic episodes that the patients experienced in the 
preceding four weeks were self-reported using the DTR-
QOL questionnaire. The frequency of adverse events was 
evaluated to assess the safety of liraglutide therapy. The 
primary outcome measure was the change of DTR-QOL 
total score from baseline. Additionally, the correlation 
between changes in HbA1c and DTR-QOL scores was 
evaluated. Secondarily, correlations between changes in 
weight and DTR-QOL scores and those between changes 
in random blood glucose levels and DTR-QOL scores 
were evaluated.
The study protocol was registered with the University 
Hospital Medical Information Network (UMIN-CTR: 
UMIN000007159) prior to the commencement of the 
study. We adhered to the “Ethical Guidelines for Clinical 
Studies” issued by the Japanese government after receiv-
ing permission from the ethical committees at each of 
the participating medical facilities, and this study was 
conducted in accordance with the ethical standards laid 
down in the Declaration of Helsinki and its later amend-
ments. All personal information was anonymized. The 
participation of patients with diabetes was obtained 
through an opt-out methodology. The patients were 
informed about the study and the ability to opt out via a 
poster. However, a written informed consent was given if 
directed by the institutional review board. To ensure data 
quality in this study, we contracted external entities for 
data collection, management, and statistical analysis.
DTR‑QOL questionnaire
We used the DTR-QOL questionnaire for evaluating 
QOL. The reliability and validity of the questionnaire 
was verified psychometrically [12], and it can be used to 
assess all modalities of diabetic treatment including injec-
tions. The self-administered questionnaire comprises 29 
questions, and the patient answers each question using 
the 7-point Likert scale ranging from “Strongly disagree” 
(−7) to “Strongly agree” (1). The score of each item was 
reversed so that “7” represented the highest QOL. When 
calculating the scores for DTR-QOL questions 26–29, 
the rating scores were reversed such that a higher score 
indicated better QOL. The assessment covers each of the 
following four domains: D1 “Burden on social activities 
and daily activities,” D2 “Anxiety and dissatisfaction with 
treatment,” D3 “Hypoglycemia,” and D4 “Satisfaction with 
treatment.” By comparing the DTR-QOL scores before 
and after initiation of a new treatment, the influence 
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and effects of the new treatment on patient QOL can 
be assessed quantitatively. The total score and domain 
scores were converted to a scale of 0–100 as described 
previously [12]. The patients filled out the DTR-QOL 
questionnaire by themselves in private, to avoid any influ-
ence of physicians and medical care providers.
Statistical analysis
Patients were excluded from the analysis if data at base-
line, week 12, or both time points were missing. We 
further excluded those who dropped out of the study or 
stopped liraglutide therapy owing to adverse effects. For 
the analysis of hypoglycemic events, we used all data, 
even when data for either of the two time points were 
missing. We calculated the total score and scores for each 
domain at both baseline and week 12, and compared 
them using a paired t test. All correlation analyses were 
performed using Spearman’s rank correlation coefficient. 
We conducted stratification analyses for DTR-QOL 
scores. DTR-QOL scores were compared using Student’s 
t test between the first and fourth groups stratified by 
quartiles of changes in HbA1c or body weight. The Wil-
coxon signed-rank test was used to compare the scores of 
each question of the DTR-QOL questionnaire at baseline 
and week 12. The frequency of hypoglycemic events was 
compared between baseline and week 12 using the Chi 
squared test, and the number of hypoglycemic events per 
patient was compared using the Wilcoxon rank-sum test. 
A paired t test was used for comparing the clinical and 
biochemical characteristics at both time points.
Based on a previous study [12], power analysis was per-
formed to detect a change of 7 points in the DTR-QOL 
total score (10% improvement), with two-sided alpha of 
5% and beta of 7.5%. Assuming a DTR-QOL total score 
at baseline ±SD of 70 ± 15 and a dropout rate of 30%, we 
calculated that at least 300 patients were needed for this 
study. All statistical tests were two-sided with an alpha 
level of 0.05 and performed using the SAS 9.3 software.
Results
Subject characteristics
In total, 304 Japanese patients were enrolled in this study. 
After enrollment, five cases were found to meet the 
exclusion criteria, ten cases dropped out, 43 cases did 
not have questionnaire data either at baseline or week 
12, and 42 cases deviated from the allowance period at 
week 12. Thus, we used data from 204 cases for analy-
ses (Fig.  1). The ten dropouts included three patients 
who stopped hospital visits and seven who dropped out 
because of adverse events: four cases presented gas-
trointestinal symptoms (constipation, loss of appetite, 
gastritis, and bloating), one case showed hypersensitiv-
ity (hives), one showed hyperglycemia, and one showed 
depression. No dropouts due to hypoglycemia were 
noted. The mean age was 59.4 ± 12.3 years, mean weight 
was 73.9  ±  17.0  kg, mean BMI (body mass index) was 
27.9 ±  5.3  kg/m2, mean HbA1c was 8.7 ±  1.5% (NGSP, 
National Glycohemoglobin Standardization Program; 
71.6 ±  16.7  mmol/mol), and the mean duration of dia-
betes was 115.0 ± 88.8 months (9.6 ± 7.4 years). In total, 
55.9% of subjects used combination therapy with sulfony-
lurea during this study (Table 1). The concomitant drugs 
used by these patients at baseline and week 12 are shown 
in Table 2, which indicated that their medication was not 
changed within 12  weeks. Concerning the dose of lira-
glutide, 91.8% of the patients started 0.3 mg/day at base-
line, and 77.0% of the patients received 0.9 mg/day after 
12 weeks (Table 3).
Effects of liraglutide on clinical and biochemical 
parameters, and incidence of hypoglycemia
The clinical and biochemical parameters at the two 
evaluated time points are shown in Table  4. The 
HbA1c change was −1.2  ±  0.1% (−13.0  ±  1.2  mmol/
mol), demonstrating a significant improvement in 
glycemic control (p  <  0.001). Body weight and BMI 
were significantly decreased (p  <  0.001 for both) by 
−1.4 ±  0.3  kg and −0.5 ±  0.1  kg/m2, respectively. Sig-
nificant decreases were also observed in total cholesterol 
(−8.4 ± 2.8 mg/dL [−0.2 ± 0.07 mmol], p = 0.003), uric 
acid (−0.2 ± 0.1 mg/dL [−11.9 ± 5.9 mmol], p = 0.025), 
and HDL-C (−1.2  ±  0.6  mg/dL [−0.03  ±  0.02  mmol], 
p = 0.041).
The proportion of patients experiencing hypoglycemic 
events during the 4 weeks prior to baseline and week 12 
were 13.8 and 15.5% (p = 0.758), respectively. The num-
ber of hypoglycemic events per patient at both time 
points was 8.1 ±  8.5 and 5.3 ±  7.4 (p =  0.150), respec-
tively (Additional file 2: Figure S1).
Effects of liraglutide on DTR‑QOL scores
Changes in DTR-QOL total score and each of the four 
domain scores are shown in Table  5. The total score 
of 198 subjects at baseline was 61.9 ± 16.2, and it was 
significantly improved to 69.7  ±  16.8 (p  <  0.001) at 
week 12. Significant improvement was also seen in all 
four domains (D1–D4; Table  5). The effect size [13] 
for the total score was 0.48. The effect sizes for the 
scores in domains D1, D2, D3, and D4 were 0.28, 0.48, 
0.23, and 0.61, respectively. The effect size was the 
largest for D4, followed by total score and D2, which 
reflected moderate effect on QOL [14]. When assess-
ing the effect for each individual question of the ques-
tionnaire, a significant improvement was observed 
for 24 of 29 questions (Table  6). However, significant 
decreases were found in the scores for Q12, “Pain due 
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to my current diabetes treatment is uncomfortable,” 
and Q13, “Gastrointestinal symptoms (nausea, pass-
ing gas, diarrhea, abdominal pain) due to my current 
diabetes treatment are uncomfortable.” No significant 
changes were found for the following three questions: 
Q5, “It is a burden getting up at a certain time every 
morning for my current diabetes treatment,” Q15, “I 
worry about low blood glucose due to my current dia-
betes treatment,” and Q25, “I am concerned that if I 
continue my current diabetes treatment, the efficacy 
(effectiveness) may diminish.”
Correlations between changes in DTR‑QOL scores 
and changes in HbA1c, body weight, and random blood 
glucose
We found a significant correlation between change 
in DTR-QOL total score and change in body weight 
(ρ  =  −0.24, p  <  0.001), but not with change in HbA1c 
Fig. 1 Flowchart of selection of patients with T2DM for the analysis
Table 1 Patient characteristics at baseline
n = 204 except for height (n = 203) and duration of diabetes (n = 197) because 
of missing data. Data are shown as the mean ± SD or the number of patients (%)
Characteristics Value
Age, years 59.4 ± 12.3
Height, cm 162.6 ± 9.6
Duration of diabetes, months 115.0 ± 88.8
Men 119 (58.3)
Macrovascular complications of diabetes 36 (17.7)
Arteriosclerosis obliterans 8 (3.9)
Coronary heart disease 19 (9.3)
Stroke 15 (7.3)
Diabetic microangiopathy 106 (52.0)
Diabetic retinopathy 49 (24.0)
Diabetic neuropathy 47 (23.0)
Diabetic nephropathy 83 (40.6)
Sulfonylurea before using GLP-1 123 (60.3)
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(ρ  =  −0.12, p  =  0.102) and random blood glucose 
(ρ = 0.03, p = 0.702). With regard to changes in the four 
DTR-QOL domain scores, we detected significant cor-
relations for the following parameters: HbA1c and D4 
(ρ = −0.22, p = 0.002), and weight and D1 (ρ = −0.18, 
p = 0.010), D2 (ρ = −0.20, p = 0.006), and D3 (ρ = −0.22, 
p =  0.002; Additional file  3: Table S1). Stratification by 
HbA1c revealed significant changes between the first 
and fourth quartiles not only in D4 score (p = 0.008), but 
also in the total score (p =  0.027; Fig.  2). Similarly, sig-
nificant differences were found in total, D1, D2, and D3 
scores between the groups of the first and fourth quar-
tiles of weight change (p  =  0.003, 0.012, 0.019, 0.016, 
respectively).
Discussion
In this study, we showed the efficacy of liraglutide, and its 
influence on changes in DTR-QOL scores, and the cor-
relations between changes in HbA1c/body weight/ran-
dom blood glucose levels and DTR-QOL scores in T2DM 
patients who did not have prior experience with injection 
therapy. Liraglutide therapy decreased HbA1c level and 
body weights, and improved patient QOL as evidenced 
by the increase in scores for 24 of 29 questions, covering 
more than 82% of the DTR-QOL questionnaire.
When compared to patients who planned to start 
first-time insulin therapy [15] or those using oral hypo-
glycemic agents (OHA) alone [16], the following fea-
tures were observed in this cohort: better glycemic 
control than patients considering insulin injections 
[15], but not better than those using OHA alone [16]; 
younger; shorter duration of T2DM; and higher BMI 
[19]. With regard to high BMI, obese T2DM patients 
with poor glycemic control in OHA therapy seemed to 
have been selected as candidates for this study in the 
hope of weight loss via liraglutide [17]. As expected, we 
observed a significant reduction in weight, BMI, and 
HbA1c at 12  weeks after liraglutide initiation. Nota-
bly, all four domains in DTR-QOL as well as the total 
score improved, which was rather unexpected because 
once-daily self-injection of liraglutide was supposed to 
pose a burden for patients or negatively influence their 
QOL [18]. We speculate that the improvement in clini-
cal parameters by the liraglutide treatment changed the 
patients’ perception of T2DM treatment from nega-
tive to positive, even though they required additional 
self-injection of liraglutide, as is clear from Table 4 and 
Fig.  2. In other words, the difficulties of daily medica-
tion and additional liraglutide injection were over-
ruled by the satisfaction associated with the beneficial 
outcomes generated by liraglutide. Another possibil-
ity is that patients felt that injection therapy turned 
out easier than expected. However, patients reported 
decreased QOL concerning side effects of liraglutide 
injection such as pain due to self-injection (Q12) and 
gastrointestinal symptoms (Q13). These results seem 
logical because gastrointestinal symptoms are well-
known side effects of the drug, and the patients enrolled 
in our study were first-time users of self-injection 
therapy. Accordingly, we believe that the results of the 
DTR-QOL questionnaire represent not only subjective 
Table 2 Concomitant drugs
Data are shown as n (%)
DPP-4 dipeptidyl peptidase-4, ACE angiotensin-converting enzyme, EPA 
eicosapentaenoic acid
Drugs Baseline (n = 204) Week 12 (n = 204)
Antidiabetic drug 140 (68.6) 138 (67.7)
 Sulfonylurea 114 (55.9) 113 (55.4)
 α-Glucosidase inhibitor 19 (9.3) 18 (8.8)
 Biguanide 47 (23.0) 49 (24.0)
 DPP-4 inhibitor 8 (3.9) 7 (3.4)
 Glinide 3 (1.5) 3 (1.5)
 Thiazolidinedione 10 (4.9) 10 (4.9)
 Other 1 (0.5) 0 (0.0)
Antihypertensive drug 121 (59.3) 123 (60.3)
 Diuretic drug 22 (10.8) 20 (9.8)
 Calcium channel blocker 75 (36.8) 77 (37.8)
 ACE inhibitor 9 (4.4) 8 (3.9)
 Angiotensin II receptor 
blocker
95 (46.6) 98 (48.0)
 Direct renin inhibitor 0 (0.0) 0 (0.0)
 α-blocker 0 (0.0) 0 (0.0)
 β-blocker 17 (8.3) 18 (8.8)
 α1β-blocker 4 (2.0) 5 (2.5)
 α2 receptor agonist 1 (0.5) 1 (0.5)
 Other 2 (1.0) 2 (1.0)
Lipid-lowering agent 117 (57.4) 118 (57.8)
 Statin 103 (50.5) 102 (50.0)
 Fibrate 12 (5.9) 12 (5.9)
 Ezetimibe 6 (2.9) 8 (3.9)
 Probucol 0 (0.0) 0 (0.0)
 EPA 0 (0.0) 0 (0.0)
 Resin 0 (0.0) 0 (0.0)
 Other 4 (2.0) 4 (2.0)
Table 3 Liraglutide dose
Data are shown as n (%)
Dose (mg) Baseline (n = 204) Week 12 (n = 204)
0.3 186 (91.2) 19 (9.3)
0.6 3 (1.5) 28 (13.7)
0.9 15 (7.4) 157 (77.0)
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reality, but also objective reality in patients who started 
liraglutide treatment.
Among the four domains of DTR-QOL, marked 
improvements were observed for D2 (anxiety and dis-
satisfaction with treatment) and D4 (satisfaction with 
treatment), reflecting the achievement of satisfac-
tion with improved clinical parameters. In particu-
lar, significantly improved scores were confirmed for 
all four questions in D4, indicating that patients with 
liraglutide treatment were satisfied and confident 
about glycemic control. A significant correlation was 
observed between the change in HbA1c and D4 score 
(ρ = −0.22, p = 0.002). Similarly, previous studies have 
demonstrated a correlation between changes in QOL 
score and HbA1c [19], with similar correlation coeffi-
cients [20, 21]. Furthermore, quartile-stratified analysis 
showed a large difference between groups of the first 
and fourth quartiles of change in HbA1c (Fig. 2), sug-
gesting an association between the change of HbA1c 
and D4.
Table 4 Clinical and biochemical parameters at baseline and at week 12 of liraglutide treatment
BL baseline, w12 week 12, RBCs red blood cells, WBCs white blood cells, BMI body mass index HbA1c hemoglobin A1c, NGSP National Glycohemoglobin 
Standardization Program, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyl transpeptidase, TC total cholesterol, HDL-C high density 
lipoprotein cholesterol, TG triglyceride
p values are the results of paired t test
Items Mean value ± SD n Change (SE) p value
Baseline Week 12
Weight (kg) 73.9 ± 17.0 72.5 ± 16.7 204 −1.4 (0.3) <0.001
BMI (kg/m2) 27.9 ± 5.3 27.3 ± 5.2 203 −0.5 (0.1) <0.001
Systolic blood pressure (mmHg) 131.1 ± 15.4 129.4 ± 16.0 203 −1.8 (1.2) 0.134
Diastolic blood pressure (mmHg) 76.0 ± 11.6 76.4 ± 12.2 203 0.4 (0.8) 0.652
HbA1c (NGSP, %) 8.7 ± 1.5 7.5 ± 1.3 203 −1.2 (0.1) <0.001
Random blood glucose level (mg/dL) 199 ± 80 170 ± 66 198 −29.0 (5.8) <0.001
RBCs (×104/μL) 459 ± 54 458 ± 50 135 −1.1 (2.5) 0.661
WBCs (/mm3) 6887 ± 1879 6913 ± 1876 135 26.4 (140.4) 0.851
Hemoglobin (g/dL) 13.9 ± 1.6 13.9 ± 1.5 135 0.0 (0.1) 0.886
Hematocrit (%) 41.6 ± 4.2 41.8 ± 4.2 135 0.2 (0.2) 0.225
Blood platelets (×104/μL) 22.5 ± 6.2 23.1 ± 5.7 134 0.6 (0.4) 0.088
AST (IU/L) 28.1 ± 20.6 26.6 ± 19.3 162 −1.5 (1.1) 0.176
ALT (IU/L) 36.1 ± 33.1 33.5 ± 29.0 160 −2.7 (1.6) 0.090
γGTP (IU/L) 50.0 ± 52.7 50.2 ± 64.8 153 0.2 (2.9) 0.943
Serum creatinine (mg/dL) 0.9 ± 1.0 0.9 ± 0.9 162 0.0 (0.0) 0.215
Uric acid (mg/dL) 5.6 ± 1.5 5.4 ± 1.4 151 −0.2 (0.1) 0.025
TC (mg/dL) 189.1 ± 36.5 180.8 ± 32.2 117 −8.4 (2.8) 0.003
HDL-C (mg/dL) 50.9 ± 12.9 49.7 ± 12.5 155 −1.2 (0.6) 0.041
TG (mg/dL) 177.9 ± 130.3 172.3 ± 100.8 166 −5.6 (7.4) 0.451
Table 5 DTR-QOL total and domain scores
The total score and domain scores were converted to a scale of 0–100
p values are the results of paired t test
Domain Score n p value Effect size
Baseline Week 12
D1: Burden on social activities and daily activities 68.2 ± 20.2 73.9 ± 19.8 204 <0.001 0.28
D2: Anxiety and dissatisfaction with treatment 51.1 ± 21.9 61.5 ± 21.9 201 <0.001 0.48
D3: Hypoglycemia 75.4 ± 26.0 81.5 ± 23.2 200 0.002 0.23
D4: Satisfaction with treatment 48.3 ± 21.5 61.4 ± 21.3 202 <0.001 0.61
Total score 61.9 ± 16.2 69.7 ± 16.8 198 <0.001 0.48
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Table 6 Results of DTR-QOL questionnaire
Scores are shown as the mean ± SD
“7” represents the highest QOL score of each item
p values are the results of the Wilcoxon signed-rank test
Domain Questions Score n p value
Baseline Week 12
D1: burden on social  
activities and daily 
activities
Q1 My current diabetes treatment interferes with my work and activities 4.9 ± 2.0 5.5 ± 1.8 204 <0.001
Q2 My current diabetes treatment limits the scope of my activities 5.1 ± 2.0 5.6 ± 1.7 203 <0.001
Q3 It is difficult to find places on time for my current diabetes treatment 5.4 ± 1.7 5.8 ± 1.6 203 0.001
Q4 My current diabetes treatment interferes with group activities and per-
sonal friendships
5.4 ± 1.8 5.8 ± 1.7 204 0.007
Q5 It is a burden getting up at a certain time every morning for my current 
diabetes treatment
5.8 ± 1.7 5.9 ± 1.5 204 0.151
Q6 With my current diabetes treatment, the restricted meal times are a 
burden
5.1 ± 1.9 5.7 ± 1.6 204 <0.001
Q7 When I eat out, it is difficult to manage my current diabetes treatment 4.8 ± 1.9 5.4 ± 1.8 203 <0.001
Q8 I feel like my current diabetes treatment takes away the enjoyment of 
eating
4.3 ± 1.9 4.8 ± 1.9 204 <0.001
Q9 With my current diabetes treatment, it is hard to curb my appetite 3.8 ± 2.0 4.6 ± 1.9 204 <0.001
Q10 The time and effort to manage my current diabetes treatment are a 
burden
5.0 ± 1.7 5.3 ± 1.7 204 0.018
Q11 I am constantly concerned about time to manage my current diabetes 
treatment
5.2 ± 1.7 5.6 ± 1.6 204 0.002
Q12 Pain due to my current diabetes treatment is uncomfortable 5.9 ± 1.6 5.4 ± 1.7 204 <0.001
Q13 Gastrointestinal symptoms (nausea, passing gas, diarrhea, abdominal 
pain) due to my current diabetes treatment are uncomfortable
5.7 ± 1.7 5.2 ± 1.9 204 0.001
D2: anxiety and  
dissatisfaction with  
treatment
Q14 I am bothered by weight gain with my current diabetes treatment 4.7 ± 2.0 5.6 ± 1.7 200 <0.001
Q19 I have uncomfortable symptoms due to hyperglycemia (high blood 
glucose)
5.0 ± 2.0 5.4 ± 1.7 200 0.012
Q20 I am worried about high blood glucose 3.5 ± 2.0 4.6 ± 2.0 199 <0.001
Q21 I am dissatisfied that my blood glucose is unstable (high and low) 3.9 ± 1.9 4.7 ± 1.7 201 <0.001
Q22 I am worried that complications might get worse with my current diabe-
tes treatment
3.3 ± 2.0 4.1 ± 2.0 201 <0.001
Q23 I get anxious thinking about living while on my current diabetes treat-
ment
3.9 ± 2.0 4.4 ± 1.9 201 0.001
Q24 I find it unbearable to think that even if I continue my current diabetes 
treatment, my diabetes may not be cured
3.9 ± 1.9 4.3 ± 1.8 203 <0.001
Q25 I am concerned that if I continue my current diabetes treatment, the 
efficacy may diminish
4.5 ± 1.8 4.5 ± 1.8 203 0.822
D3: hypoglycemia Q15 I worry about low blood glucose due to my current diabetes treatment 5.3 ± 1.8 5.5 ± 1.6 201 0.100
Q16 I am scared because of low blood glucose 5.6 ± 1.7 6.0 ± 1.5 200 <0.001
Q17 I am sometimes bothered by low blood glucose 5.7 ± 1.7 6.1 ± 1.4 200 0.001
Q18 Symptoms due to low blood glucose are uncomfortable 5.6 ± 1.8 5.9 ± 1.6 199 0.002
D4: satisfaction with  
treatment
Q26 Overall, I am satisfied with my current blood sugar control 3.2 ± 1.7 4.3 ± 1.8 202 <0.001
Q27 With my current diabetes treatment, I am confident that I can maintain 
good blood glucose control
3.7 ± 1.6 4.6 ± 1.5 202 <0.001
Q28 I am hopeful about the future with my current diabetes treatment 4.5 ± 1.5 4.9 ± 1.4 204 0.001
Q29 With regards to diabetes treatment, I am satisfied with current treatment 
methods
4.1 ± 1.5 5.0 ± 1.4 204 <0.001
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The combination of liraglutide therapy with OHA 
treatment was expected to increase the risk and fear 
of hypoglycemic events. In contrast, it resulted in the 
improvement of D3 (hypoglycemia). However, the num-
ber of patients who experienced hypoglycemic events, 
and the number of hypoglycemic events per patient did 
not change after the initiation of liraglutide therapy. We 
consider that the increase in D3 score was because of 
the improvement in clinical parameters without a rise in 
hypoglycemic events.
Weight change was negatively correlated with changes 
in the DTR-QOL total score and D1–D3, indicating that 
the greater the weight loss, the higher the QOL. Changes 
in these scores were as high as 8.6–14.8 in the first quartile 
groups of body weight change and as low as 0.8–4.6 in the 
fourth quartile groups (Fig. 2), strongly supporting the asso-
ciation between increase of QOL and body weight reduction.
There are several limitations to this study. First, it was a 
single-arm, pre-post observational study without control 
arm. Owing to this limitation, we do not know whether 
the results obtained include a placebo effect. A subset of 
patients might lose weight in response to the self-injection 
of placebo, and weight loss alone (independent of treat-
ment) could provide combined improvement in HbA1c 
and QOL indicators seen in the study. Second, we excluded 
the data of 43 patients for whom we did not have data at 
both baseline and week 12. Therefore, it is difficult to 
extrapolate the findings of this study to all T2DM patients. 
Nonetheless, this study demonstrated that the injection of 
liraglutide along with OHA treatment reduced the body 
weight, BMI, and HbA1c level, and improved QOL, except 
for the gastrointestinal symptoms and pain associated with 
liraglutide injection, in obese T2DM patients. Physicians 
sometimes hesitate to initiate the use of injection thera-
pies. However, this study revealed that self-injection does 
not necessarily deteriorate the patient’s QOL. Based on the 
routine subjective assessment of patient QOL, patients and 
physicians can select better treatment options.
Conclusions
In conclusion, liraglutide is an effective treatment option 
for obese T2DM patients, and it helps in reducing body 
weight and improving glycemic control without deterio-
rating QOL.
Additional files
Additional file 1. List of medical facilities.
Additional file 2: Figure S1. Figure showing hypoglycemic events 
before and after liraglutide treatment.
Additional file 3: Table S1. Table describing the correlation between 
domain scores and HbA1c, body weight, and random blood glucose.
Fig. 2 Changes of DTR-QOL scores in each quartile of the change of HbA1c or body weight. The changes in the total DTR-QOL score and each 
domain score between baseline and 12 weeks after the initiation of liraglutide in each quartile of change in HbA1c and body weight are shown
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